Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach
2023 · BMC Cancer · 7 citations
https://doi.org/10.1186/s12885-023-10938-8
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
6
Papers
28
Citations
3
h-index
1
i10-index
Ruomeng Song is an academic researcher from China Medical University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Health Systems, Economic Evaluations, Quality of Life & Tuberculosis Research and Epidemiology. The author has an h-index of 3, co-authored 6 publications.
https://doi.org/10.1186/s12885-023-10938-8
https://doi.org/10.1186/s12874-025-02519-z
Click to start Chat